SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Oxford GlycoSciences Plc
An SI Board Since January 2000
Posts SubjectMarks Bans
469 13 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
319This is not a generous bid, but as I hold decent amounts of both companies, I donigel bates-1/23/2003
318LONDON -(Dow Jones)- Cambridge Antibody Technology and Oxford Glycoscienses saidnigel bates-1/23/2003
317Actelion 2002 Operating Revenues at CHF 140.3 Million Thursday January 23, 2:29 scaram(o)uche-1/23/2003
316OXFORD, England, Jan. 17 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (Nasnigel bates-1/17/2003
315The first claims of the issued U.S. patents are very broad, and virtually every scaram(o)uche-1/15/2003
314(FWIW)... BOSTON--(BUSINESS WIRE)--Jan. 15, 2003-- GlycoGenesys, Inc. (NASDAQ:Gnigel bates-1/15/2003
313OXFORD, England, Jan. 15 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (Nasnigel bates-1/15/2003
312Nice... : ) JeffEVENT HORIZON III-1/14/2003
311Cool. Thanks very much for finding that. (eom)scaram(o)uche-1/13/2003
310ABINGDON, England, Jan. 13 /PRNewswire/ -- Confirmant Ltd., a provider of innovanigel bates-1/13/2003
309Mol Microbiol 2003 Jan;47(2):453-61 Glycolipid depletion in antimicrobial therascaram(o)uche-1/12/2003
308blocks. Two at 50K, don't know if it's double count. (eom)scaram(o)uche-1/8/2003
307OGS Signs Proteomics Contract with Pfizer Tuesday January 7, 2:03 am ET OXFORDscaram(o)uche-1/7/2003
306Actelion presentation...... Zavesca.... "ideal drug for Actelion" scaram(o)uche-1/6/2003
305ADRs. I'm a little bit right, a little bit wrong: 160.254.123.37keokalani'nui-12/30/2002
304<i>Over the past five years the company has had an average of only three inigel bates-12/30/2002
303I was remebered wrongly - Message 17032922 It was $1m in cash and equity, withnigel bates-12/30/2002
302Without really, actually, truly knowing.... Whether the ADR trades or not in thkeokalani'nui-12/29/2002
3012002 Week 3 Oxford GlycoSciences has five applications concerned with nucleicJohn McCarthy-12/29/2002
300businessweek.com (emphasis mine) DECEMBER 26, 2002 NEWSMAKER Q&A:TECHNOLscaram(o)uche-12/29/2002
299USE OF GLUCOSYLCERAMIDE SYNTHESIS INHIBITORS IN BRAIN CANCERTHERAPY Patent Numscaram(o)uche-12/29/2002
298DIAGNOSIS AND TREATMENT OF VASCULAR DEMENTIA Patent Number: Publication datscaram(o)uche-12/29/2002
297DIAGNOSIS AND TREATMENT OF BREAST CANCER Patent Number: Publication date: 2scaram(o)uche-12/29/2002
296<i>A number of companies are using technology that's probably in violanigel bates-12/28/2002
295<i>...human proteins. But I've heard them talking about something on tnigel bates-12/28/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News